The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

Mumbai: Piramal Pharma has announced that the Company has received six observations from US Food and Drug Administration ...

Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

Larsen & Toubro (L&T) has acquired the balance 26% stake in L&T Special Steels and Heavy Forgings (LTSSHF), an existing subsidiary of the company, from Nuclear Power Corporation of India (NPCIL) and ...

Piramal Pharma Ltd share price was down by -7.81% from the previous closing price of ₹200.56. Who are peers of Piramal Pharma Ltd? The peers of Piramal Pharma Ltd are Sun Pharmaceuticals ...

Piramal Pharma Limited said, "FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance ...

Stocks like Indian Overseas Bank, Larsen & Toubro, Container Corporation of India, Cello World, RBM Infracon, Bharti Airtel, ...

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.